Evidence map›Paper›PMID 42328002›Full record

ArticleGlobal journal on quality and safety in healthcare2026

The Societal and Economic Burden of COPD in Saudi Arabia.

Gihan El-Sisi, Waleed AlSowayan, Yahya Habis, Amr Alwakeel, Hussein Aljuwayed, Bader Jammah Alghamdi, Riyad Al-Lehebi, Nesreen Tayeb, Yousra Hamid, Aljawharah Alkoraishi and 3 more

Abstract read
In one paragraph

Article in Global journal on quality and safety in healthcare, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gihan El-SisiHTA Office, Cairo, Egypt.ORCID https://orcid.org/0000-0002-2917-9388
Waleed AlSowayanPulmonary Division, Internal Medicine Department, Security Forces hospital, Riyadh, Saudi Arabia.
Yahya HabisDepartment of Internal Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Amr AlwakeelDepartment of Medicine, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
Hussein AljuwayedPulmonology Department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Bader Jammah AlghamdiKing Saudi bin Abdulaziz for Health Science, National Guard Ministry, Jeddah, Saudi Arabia.
Riyad Al-LehebiCollege of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
Nesreen TayebPulmonology Department, King Fahd Armed Forces Hospitals, Jeddah, Saudi Arabia.
Yousra HamidHTA Office, Cairo, Egypt.
Aljawharah AlkoraishiPharmacy Department, King Saud University Medical City, Riyadh, Saudi Arabia.
Nabila S Ben SlimanePharmaceutical Care Division, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia.
Maha AbushalPharmacy Department, Prince Sultan Military Hospital, Riyadh, Saudi Arabia.
Wedad AlnemariSanofi, Greater Gulf Multi-Country Organization, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is a chronic, inflammatory, progressive respiratory disease characterized by chronic symptoms, such as cough, dyspnea, and expectoration, owing to persistent airway abnormalities that can lead to airflow limitations and inflammation, increasing the risk of exacerbations. Exacerbations are a characteristic feature of moderate and severe COPD, and they are considered a main cause of morbidity, mortality, and reduced quality of life. Patients with moderate to severe COPD are more susceptible to future exacerbations, which usually necessitate hospital admission and readmission, imposing a devastating burden on patients' quality of life and daily activities while posing an enormous burden on healthcare systems. This study aimed to assess the societal and economic burden of different COPD severity stages and their associated events among adult patients in Saudi Arabia over a 10-year period. Methods: A prevalence- and incidence-based cost-of-illness Markov model was constructed in Microsoft Excel 365 to estimate the direct medical and indirect costs incurred by patients with COPD in Saudi Arabia. The model projects the burden over 10 years. We developed a state-transition Markov model comprising five health states defined by exacerbation status. The five health states included: no exacerbations, one moderate exacerbation; two or more moderate exacerbations; one or more severe exacerbations; and death. Based on the ABE scheme classification in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, we mapped the health states accordingly; the no exacerbation state was considered equivalent to A Results: The total cost per patient per year was estimated at SAR 273,874 ($148,040 USD). The percent of work impairment among patients with moderate or severe exacerbations of COPD was the most impactful parameter that could increase costs. Conclusion: COPD imposes a substantial and growing burden on the Saudi economy, both in terms of direct and indirect medical costs. Our findings underscore the need to adopt policies that ensure comprehensive prevention and management strategies.

Indexed as

COPDcostsEconomic burdenSaudi Arabiasocietal

Identifiers

PMID42328002
PMCPMC13281272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.